Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy
of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)